Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Cancer × Gemcitabine × Clear all

Phase

Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 257 Carcinoma, Non-Small-Cell Lung 138 Lung Neoplasms 77 Urinary Bladder Neoplasms 72 Breast Neoplasms 72 Cholangiocarcinoma 51 Neoplasms 44 Neoplasm Metastasis 44 Ovarian Neoplasms 35 Biliary Tract Neoplasms 35 Lymphoma, Large B-Cell, Diffuse 27 Sarcoma 25 Lymphoma 25 Recurrence 23 Nasopharyngeal Carcinoma 22 Gallbladder Neoplasms 22 Hodgkin Disease 21 Carcinoma, Transitional Cell 21 Adenocarcinoma 21 Adenocarcinoma of Lung 19 Bile Duct Neoplasms 18 Triple Negative Breast Neoplasms 15 Fallopian Tube Neoplasms 15 Carcinoma, Ovarian Epithelial 14 Urethral Neoplasms 13 Colorectal Neoplasms 13 Carcinoma, Renal Cell 13 Lymphoma, Non-Hodgkin 12 Leiomyosarcoma 12 Carcinoma 12

Interventions

relatlimab 2 linrodostat 2 Nivolumab 2 Ipilimumab 2 Vorinostat 1 Trastuzumab 1 IFL protocol 1 Gemcitabine 1 Dasatinib 1 Cetuximab 1 BMS-813160 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05605509 2026-02-06

RP-6306 in Patients With Advanced Cancer

Canadian Cancer Trials Group

Phase 2 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡